NEW YORK – Bionano Genomics announced Thursday preliminary first quarter revenues of $1.1 million, down sharply from revenues of $1.9 million in the first quarter of 2019.
The San Diego-based genome mapping company also said in a statement it is "suspending any guidance, anticipated timelines or other outlooks previously provided for 2020," due to uncertainty created by the COVID-19 pandemic.